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Racial differences in renal allograft survival: The role of systemic
hypertension. The rate of decline in the number of functioning renal
allografts beyond the first year after transplantation has changed little in
the last 25 years, and during long-term follow-up most allografts are lost
due to chronic transplant rejection or patient death. The recipient race
correlates with allograft survival, and African American recipients have a
lower allograft survival than Caucasians. The goal of the present study was
to identify clinical variables present during the first six months after
transplantation that predict the loss of renal allografts beyond six months
after transplantation, and in particular to determine the role of systemic
hypertension on renal allograft survival in black and white recipients. This
study includes 547 recipients of first cadaveric renal allografts performed
at The Ohio State University. All patients were treated with a uniform
immunosuppressive protocol and had a follow-up of at least three years.
By multivariate analysis the following variables correlate with poor
allograft survival: an elevated serum ereatinine concentration measured
six months after transplantation (SCr6,,0) (P < 0.0001); black race (P <
0.0001); increasing numbers of acute rejection episodes (ATR) (P =
0.002); and young recipients (P = 0.026). Allograft survival is significantly
worse in black (mean allograft half-life of 7.7 1.3 years) than in white
recipients (24 3 years) (P < 0.0001). Black recipients also have a
significantly higher six month average mean arterial blood pressure
(MAP) (105 8 mm Hg) than white recipients (102 7 mm Hg) (P
0.002). However, the prevalence of hypertension is not significantly
different in black (33%) than in white recipients (26%). Furthermore,
increasing MAP levels correlate with a shorter allograft half-life in black
recipients (P = 0.0002), but not in white recipients (P = 0.84). Allograft
survival was eight times shorter in hypertensive black (3.1 0.7 years)
than in hypertensive white recipients (24.6 7 years). In contrast,
allograft survival was not statistically different between normotensive
black and white patients. In conclusion, the presence of poorly controlled
systemic hypertension, early after renal transplantation, correlates with
poor allograft survival in black recipients. Thus, systemic hypertension
may explain, in part, differences in renal allograft survival between black
and white patients.
Over the last 20 years, renal allograft survival rates during the
first year after transplantation have improved dramatically. In
contrast, the rate of decline in the number of functioning renal
allografts beyond one year post-transplant has improved little in
the recent past [1, 21. The two leading causes of late renal allograft
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loss are patient death and chronic transplant rejection (CTR).
Despite new immunosuppressive medications and regimens, the
incidence of CTR remains unchanged, and long-term patient
survival has improved little since 1985 [1—3]. Clearly, future
improvements in renal allograft survival will depend on a better
understanding and treatment of CTR and in the prevention of
both CTR and patient death.
CTR is an ill-defined entity characterized clinically by progres-
sive deterioration of renal allograft function late after transplan-
tation and, pathologically, by interstitial scarring, tubular atrophy,
fibrointimal hyperplasia of blood vessels, and glomerulosclerosis
[3, 4]. These diagnostic criteria are non-specific, and consequently
it is likely that several pathogenic mechanisms contribute to the
development of CTR. For example, acute rejection episodes [2,
5—7] and histocompatibility (HLA) mismatching [8, 9] correlate
with the development of CTR, suggesting that immunologic
mechanisms contribute to the pathogenesis of CTR. Nonimmu-
nologic mechanisms may also play a role in the pathogenesis of
CTR [2, 10]. Thus, it has been postulated that reductions of renal
mass, secondary to any etiology, may lead to glomerular hyper-
tension, hyperfiltration and hypertrophy, alterations that under
other clinical and experimental circumstances may lead to pro-
gressive glomerular damage and loss of renal function [10]. In
addition, the prolonged use of cyclosporine (CsA) may be asso-
ciated with progressive renal allograft damage [11, 12]. In con-
trast, recent studies did not demonstrate a progressive deteriora-
tion of glomerular filtration rate in renal allograft recipients
treated with CsA [13].
In some patients the treatment of CTR, once the serum
creatinine begins its progressive rise, is only effective in slowing
down the progression of the disease [14—16]. Thus, a more
successful therapeutic approach to CTR will require a better
understanding of its pathogenesis and an early diagnosis. In the
present study we tested the postulate that long-term renal al-
lograft survival can be predicted by clinical variables during the
first six months after renal transplantation. Furthermore, we
postulate that systemic hypertension may be a risk factor for renal
allograft loss. Previous studies have shown that systemic hyper-
tension is common after transplantation [17] and that poorly
controlled blood pressure, beyond one year after transplantation,
is associated with poor allograft survival [14, 18, 19]. However, to
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our knowledge, no previous study has evaluated whether hyper-
tension, early after transplantation, correlates with long-term
renal allograft survival, nor whether there is an association
between systemic hypertension and the survival of renal allografts
in black and white recipients. The postulate that systemic hyper-
tension may be particularly deleterious for the renal allografts in
black recipients is suggested by the higher incidence of hyperten-
sive nephrosclerosis in black patients [201, and it is indeed possible
that allograft nephrosclerosis has a negative impact on the survival
of renal transplants in black recipients.
Methods
Patient selection
The present study is based on a retrospective analysis of clinical
records from 547 patients who received their first cadaveric
(CAD) renal transplant at The Ohio State University between
September 1982 to July 1990, at least three years before the
initiation of the present study. All patients were treated with a
uniform immunosuppression protocol that included [21], in the
immediate post-transplant period, Minnesota anti-lymphocyte
globulin at a dose of 15 mg/kg for at least five days, prednisone
starting at 2 mg/kg p.o., and azathioprine at 1 to 2 mg/kg.
Cyclosporine (CsA) was initiated at a dose of 8 to 10 mg/kg p.o.
when the serum creatinine reached a concentration of 2.5 mg/dl.
Subsequently, the CsA dose was adjusted downward if the serum
creatinine concentration increased. Based on previous studies
[22], no rigid HLA matching criteria were used to allocate renal
allografts to particular recipients. Ninety-three percent of donors
were Caucasians.
Acute transplant rejection (ATR) was diagnosed in all patients
who had acute deterioration of renal allograft function and
demonstrated, by kidney biopsy, the presence of ATR [4]. Be-
cause the purpose of the present study is to assess the predictive
value of clinical events during the first six months post-transplant,
only those ATR episodes that occurred during those first six
months were analyzed as risk factors for graft losses that occurred
beyond six months post-transplant. The return of a patient to
hemodialysis or peritoneal dialysis on a permanent basis was
considered as an allograft loss. Patients dying with functioning
allografts were not considered as allograft failures; that is, data
were right censored at patient death.
Systemic blood pressures (BP) were measured by the patients at
home and reported to our post-transplant office. A total of 40,130
BP recordings were reported by 97% of the patients during the
first six months post-transplant corresponding to a mean of 60
18 SD BP determinations per patient. For each patient, the BP
was calculated as the average of all mean arterial pressures [MAP
= (systolic BP — diastolicBP)13 + diastolic BP] recorded over the
first six months after transplantation. We considered a MAP 
107 (approximately 140/90) as indicative of hypertension. Most
patients included in the study were receiving antihypertensive
medications. Thus, the designation of a patient as hypertensive
should be interpreted as a patient whose BP was poorly controlled
on medications.
Statistical analysis
Data are expressed as the mean standard deviation (SD)
except where designated as mean standard error (sEM). Student
t-tests were used to compare two means and Fisher's exact tests
Table 1. Clinical characteristics of the study population
Patient's characteristics
Gender
Males 330
Females 217
Race
Whites 429
Blacks 104
Other 14
Age
Follow-up (after 1st 6 months)
Systolic BP (average 1st 6 months)
Diastolic BP (average 1st 6 months)
MAP (average 1st 6 months)
CsA dose (average 1st 6 months)
43 13 years
4.6 2.6 years
143 13 mm Hg
82 8 mm Hg
102 8 mm Hg
6.2 1.4 mg/kg/day
Values represent means SD.
were used to compare two proportions. All tests were two-tailed.
Allograft survival data were analyzed with the Cox proportional
hazards. The impact of covariates on graft survival was tested
using first univariate and then multivariate regression analysis
assuming that the rate of allograft losses beyond six months
follows an exponential curve. Statistical significance was calcu-
lated as the significance of the coefficients in the proportional
hazards model. Allograft half-lives, that is the number of years of
follow-up after the first six months required to lose 50% of the
allografts, were calculated as ln(2)/k, where k is the hazard
function expressed as the fractions of grafts lost per year (number
of grafts lost/total of months of follow-up for the population) [2,
23]. Survival curves were calculated using the Kaplan-Meier
method [24].
Results
Patient characteristics
Table 1 displays the characteristics of the patient population.
Ninety-two patients (17%) died during the follow-up period.
Ninety-three grafts (17%) were lost after a mean follow-up of 33
25 months (range 6 to 104 months). During the first six months
post-transplant, 234 patients (43%) had ATR episodes. Of those
patients, 107 (20% of the total population) had one ATR, 58
patients (11%) had two, and 59 patients (13%) had three or more.
Relationships between long-term graft survival and clinical
parameters during the first six months post-transplant
Table 2 displays the univariate and multivariate analysis of early
post-transplant clinical parameters versus long-term allograft
survival. As can be seen by multivariate regression analysis, four
variables predicted the loss of renal allograft: higher serum
creatinine concentration six months after transplantation
(SCromo) (P < 0.0001); more ATR episodes during the first six
months post-transplant (P < 0.0001); black recipient race (P =
0.007); and younger recipient age (P = 0.01). It should be noted
that MAP was significantly associated with allograft survival when
considered in a univariate analysis but not when it was considered
in a multivariate analysis together with the recipient race.
The SCrom) concentration increased progressively in patients
with increasing numbers of ATR episodes (r 0.346, P < 0.0001);
however, neither variable completely explained the effect of the
other on allograft survival. This is best demonstrated in Figure 1
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Table 2. Relationship between clinical parameters collected during the
first 6 months after transplant and long-term allograft survival
Parameter
Regression analysis
Univariate Multivariate
Recipient gender 0.3k'
Recipient age 0.003 0.01
Recipient race 0.007 0.007
MAP (1st 6 months) 0.002 0.08
HLA matching (AB+DR) 0.3 —
ATR (1st 6 months) <0.0001 <0.0001
CsA dose 0.01 0.14
Cromo <0.0001 <0.0001
a P values < 0.05 were considered as statistically significant
Fig. 1. Relationships between SCr6 ,,,,,, ATR number and renal allograft
survival, the latter expressed as allograft half-life (mean SEM, y axis). The
number of ATR, 0, 1, or 2 and more ATR (2+), is displayed in the x axis.
Patients are subdivided into two groups: those with SCr6,,0 < 2 mgldl (LI)
and patients with SCr6mo  2 mgldl (). Numbers in parenthesis above the
bars represent the numbers of patients in each group.
which displays allograft survival, expressed as allograft half-life, in
patients with zero, one, or two or more episodes of ATR and a
SCrsmo lower or higher than 2 mgldl. As can be seen in Figure 1,
increasing numbers of ATR episodes were associated with a
progressive decline in allograft half-life both in patients with
SCromo <2 mg/dl and in patients with SCromo 2 mgldl (P <
0.0001 both groups). In addition, patients with a SCramo 2 mg/dl
demonstrated a lower allograft half-life than patients with SCr6mo
<2 mg/dl, even when patients had the same number of ATR
episodes (P < 0.0007) (Fig. 1). Although not shown here, allograft
half-lives did not differ significantly between patients with two
ATR and those with more than two ATR.
The effects of race and systemic hypertension on long-term
allograft survival
The recipient race was a major predictor of allograft survival.
For example, graft losses occurred in 34 out of 104 (33%) black
recipients and in 59 out of 429 (14%) white recipients (P
0.00007). Expressed in other terms, the calculated allograft half-
life was 7.7 1.3 SEM years in black recipients and 24.1 3 years
in white recipients (P < 0.0001). The study population included 14
transplant recipients who were not African American or Cauca-
Table 3. Prevalence of factors potentially associated with poor allograft
survival in black and white recipients
Parameter
Recipient race
African American Caucasian P
SCr6mo, mg/dl 2.0 1.4 1.8 0.7 0.04
Number of 1.1 1.6 0.9 1.5 NS
ATR/patient
Recipient's age
Delayed graft functio&'
44.3 12
11%
42.4 14
6%
NS
NS
HLA matching (A,B)a 0.9 0.9 1.4 1.1 0.0001
HLA matching, (DR)C
CsA dose, mglkgd
CsA level, nglmld
0.4 0.6
6.3 1.5
73 52
0.6 0.7
6.2 1.3
66 48
0.001
NS
NS
Diabetes, % 24% 23% NS
MAP, mm Hg1 104.7 7.6 102 7.5 0.001
a Values represent means SD.lDelayed graft function is defined as the need of hemodialysis, for any
period of time, during the first 2 weeks following transplantation.
Average number of HLA matches between donor and recipient.
dAverage dose, or level, of CsA during the first six months after
transplantation.
NS is Not statistically significant.
MAP during the first 6 months of transplantation.
sian, a number insufficient to analyze the relationship between
these other races and allograft survival.
In an attempt to explain racial differences in allograft survival,
we examined the presence of variables potentially associated with
poor allograft outcomes in black and white recipients (Table 3).
Among those variables, the SCr6mo concentration was significantly
higher in black than in white patients, and HLA matching was
significantly worse in black than in white patients. However, by
multivariate analysis, these differences explained little of the
effects of recipient race in allograft survival. In addition, the six
month average MAP was significantly higher in black recipients
(104.7 7.6 mm Hg) than in white recipients (102 7.5 mm Hg)
although the difference was small. There were no differences
between black and white recipients in the number of ATR
episodes per patient, the recipient's age, the incidence of delayed
allograft function, the dose of CsA, the average CsA levels for the
first six months post-transplant, and the percentage of patients
with diabetes (Table 3). Furthermore, there was no objective
evidence of differences in patient compliance between black and
white recipients. Thus, (1) the number of CsA level determina-
tions per patient, during the first six months post-transplant, was
not different in black (15.8 14) or white recipients (15.8 13);(2) The number of times that the CsA level was below the
detectable range for the assay was also not different in black
patients (9% of all determinations) and white patients (12%); (3)
96% of black recipients and 96.5% of white recipients recorded
their BP at home and reported those results to the post-transplant
office; and (4) the number of BP determinations per patient was
similar in black (62 24 measurements per patient) and white
recipients (69 20).
Based on the results noted above, we performed an analysis of
risk factors for allograft loss independently in black and in white
recipients. Table 4 summarizes the results of this analysis. In white
recipients, as in the overall population, the following variables
predicted the loss of the allograft: an elevated SCr6mo; more ATR
episodes during the first six months; and a younger recipient. In
black recipients an elevated SCrom,, and a younger recipient were
-
(241)
(98)
(53)
1
Number of ATR
30
20 (30)
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Table 4. Relationships between clinical variables during the first 6 100
months after transplantation and allograft survival in black and
white recipients
Parameter
-
White recipients Black recipients
Univariate Multivariate Univariate Multivariate
Recipient gender
Recipient age
SCromo, mg/dl
Number of ATR
0.17'
0.013
<0.0001
<0.0001
—
0.03
<0.0001
0.001
0.86
0.008
<0.0001
0.07
—
0.006
<0.0001
—
MAP (average
1st 6 months)
HLA matching
CsA dose
0.15
0.88
0.06
—
—
—
<0.0001
0.45
0.2
0.0009
—
—
a p values derived from Cox regression analysis
(118)
• [•II[_ (29)
(59)
Number of ATR
Fig. 2. Relationships between A TR number, race and renal allograft survival,
the latter expressed as half-lift (mean SEM, y axis), in white (L) and black
recipients (). Numbers in parenthesis above the bars represent the
numbers of patients in each group.
also associated with a poor allograft outcome. However, the
number of ATR was not statistically related to allograft survival in
black recipients. Furthermore, the allograft survival in black
recipients was also adversely affected by poorly controlled sys-
temic hypertension during the first six months following transplan-
tation.
The relationship between ATR number and allograft survival in
black and white recipients is re-examined in Figure 2. In white
recipients, increasing numbers of ATR were associated with a
progressive decline in allograft half-life (P < 0.0001). In contrast,
the same relationship was not demonstrable in black recipients (P
0.21). It is interesting to note that the largest difference in
allograft survival between black and white recipients occurred in
those patients who had no ATR episodes (P < 0.0001). Indeed, in
patients who had two or more ATR episodes, the allograft survival
was not statistically different between black and white recipients.
These results suggest that factors other than number of ATR are
important determinants of the difference in allograft survival
between black and white recipients.
Based on the above observations, we next assessed the effects of
poorly controlled systemic hypertension on renal allograft survival
in black and in white recipients. The prevalence of poorly
controlled hypertension was not significantly different in black
(33%) and white recipients (26%). However, the six month
80
average MAP was significantly higher in black than in white
patients (Table 3), and hypertensive black recipients had signifi-
cantly higher blood pressure levels than hypertensive white recip-
ients (112.8 5.1 and 110.6 3.7 mm Hg, respectively) (P =
0.009). Figure 3 displays Kaplan-Meier allograft survival curves in
black and in white recipients subdivided according to the presence
or absence of hypertension. It can be seen that hypertensive black
recipients had significantly lower allograft survival than the three
other groups of patients (P < 0.0001 vs. all groups). In contrast,
there were no significant differences in allograft survival among
normotensive black recipients and normotensive or hypertensive
white recipients.
The relationship between poorly controlled hypertension and
allograft survival in black recipients was not due to poor compli-
ance in this particular group of patients. Thus, objective param-
eters of patient compliance (including number of CsA level
determinations per patient, number of times that the CsA level
was below detectable levels, percent of patients reporting BP, and
number of reported BP per patient) were not significantly differ-
ent between hypertensive black recipients and other groups of
patients (data not shown).
Discussion
The present analysis identified risk factors present during the
first six months after renal transplantation that predict the loss of
cadaveric renal allografts during long-term follow-up. Among
those risk factors, we showed that the presence of poorly con-
trolled systemic hypertension early after transplantation is asso-
ciated with poor allograft survival in black recipients. Further-
more, the present results support the postulate that the
relationship between hypertension and poor survival is due to the
deleterious effects of hypertension on the renal allograft. For
example, the relationship between blood pressure and graft
survival was statistically independent of renal function (Table 4)
and was demonstrated only in black recipients. The postulated
role of hypertension on renal allograft survival in black recipients
is also consistent with the observation that hypertensive nephro-
sclerosis of native kidneys is more common in African Americans
than in Caucasians [201. It has been suggested that the racial
00 60
40
U)
20
0
Time, years
Fig. 3. Kaplan-Meier plots of renal allograft survival in normotensive Cau-
casians (MAP < 107) (O----O), hypertensive Caucasians (MAP  107)
(fl----), normotensive African American (•----•), and hypertensive Afri-
can American ----•).
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disparity in the prevalence of hypertensive nephrosclerosis may be
due to higher levels of blood pressure in black than in white
patients, racial differences in the characteristics of hypertension,
and/or racial differences in the renal responses to hypertension
[201. The present studies may help clarify these mechanisms.
Thus, in the present patient population MAP levels were higher in
hypertensive black recipients than in white recipients. However,
that small difference (mean of 2 mm Hg) cannot explain the
striking racial differences on the effects of hypertension on renal
allograft survival. Furthermore, 93% of black recipients in the
present study received kidneys from white donors. Thus, the poor
allograft outcomes in hypertensive black recipients cannot be
ascribed to a special sensitivity of the kidney of African Americans
to hypertension. Supporting this conclusion, analysis of large
databases did not show a significant impact of donor race on
long-term allograft survival [2].
The lack of statistically significant correlation between MAP
and renal allograft survival in white recipients should be inter-
preted with caution. We believe that these data indicate not that
hypertension is unimportant in white recipients, but rather that
other factors are relatively more important determinants of
allograft survival in Caucasians. Indeed, we believe that hyperten-
sion should be treated aggressively in any allograft recipient. In
the present study we did not do a detailed analysis of the
antihypertensive medications used in our patients. However, the
large majority of transplant patients in our institution are treated
with primarily with diuretics and calcium channel blockers, and
angiotensin converting enzyme inhibitors are avoided early after
transplantation.
Previous studies suggested that racial differences in allograft
survival may be explained, in part, by immunologic differences
between black and white recipients [25]. Indeed, in this patient
population there were significant racial differences in HLA match-
ing between black and white recipients. However, the present
analysis does not support the contention that these HLA matching
differences explain the poor allograft outcomes of black recipi-
ents. In fact, in the present study HLA matching did not correlate
with allograft survival in either black or white patients. These
results are in contrast with previous studies [25], and this discrep-
ancy may be due to the fact that our patients were poorly HLA
matched, thus limiting the power to detect the effects of HLA
matching on allograft survival. Also, against the contention that
racial differences in allograft survival are mainly due to immuno-
logic differences, is the observation that the number of ATR was
not different in black and in white recipients. In fact, the most
striking racial difference in allograft survival was demonstrated in
individuals who never had an ATR episode. Previous studies
agree with our conclusion that HLA matching cannot explain the
shorter allograft survival in African Americans compared to
Caucasians [26, 27]. In addition, this and other studies have
identified additional factors that may partially explain racial
differences in allograft survival. Those factors include an effect
due to the transplant center, socioeconomic factors, recipient age,
and patient compliance [25, 28—30]. The results of the present
single center study suggest that the relationship between poorly
controlled hypertension and allograft survival in black patients
cannot be attributed to differences in the recipient's age or the
patient's compliance. The present analysis is consistent with the
postulate that several pathogenic events participate in the devel-
opment of CTR. Furthermore, it is possible that the relative
importance of each these pathogenic factors may vary among
transplant centers due to differences in the patient population
and/or clinical practices.
We and others have previously demonstrated that increasing
numbers of ATR have a negative impact on long-term renal
allograft survival [2, 5, 6]. The present analysis extends those
observations by demonstrating that allograft survival is particu-
larly poor in those individuals who have both ATR and an
elevated SCR6m0. In fact, the present study indicates that SCR6,,0
prognosticates allograft survival independently from ATR num-
ber. This concept is also supported by previous studies showing
that the Sr concentration on discharge from the hospital after
renal transplantation predicts allograft survival [31, 32]. The
reasons for the relationship between SCromo and allograft survival
may vary according to the etiology of the elevated SCromo. For
example, in some patients an elevated SCromo may be due to
allograft damage that occurred in the past, perhaps at the time of
transplantation, or may be related to preexisting pathology in the
donor organ. In those patients, the correlation between SCr6mo
and allograft survival may be due to the long-term deleterious
effects of the hemodynamic adaptation to reduced functional
renal mass [10]. In other patients, a persistently elevated Sr may
be an indicator of ongoing immunologic and/or non-immunolog-
ically mediated allograft damage which eventually results in
allograft loss. For example, an elevated 5Cr early after transplan-
tation may be indicative of ongoing subclinical episodes of ATR
[33], CsA toxicity, and/or hypertensive nephrosclerosis. Based on
these considerations, we believe that persistent elevations in S.
(>2 mg/dl) early after transplantation should be investigated, and
that investigation may require the performance of a kidney biopsy.
Previous studies showed that at the time of diagnosis, patients
who had CTR were taking a lower dose of CsA than were those
patients without evidence of CTR [5]. The present analysis cannot
evaluate this relationship because in our transplant program the
dose of CsA is adjusted according to the serum creatinine level,
and consequently patients with high creatinine levels are treated
with lower CsA doses.
The findings of the present study and other studies [31, 321
highlight the concept that the pathogenic mechanisms responsible
for CTR are initiated early after transplantation. Consequently,
clinical variables, such as those described here, can be used to
identify patients at higher risk for CTR early after transplantation.
This early identification will allow us, in the future, to perform
prospective studies to test the effectiveness of preventive mea-
sures and therapeutic maneuvers for CTR. This study also sug-
gests that BP control after transplantation may have profound
beneficial effects in the survival of cadaveric renal allografts in
black recipients.
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